Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca ( (GB:AZN) ) has shared an update.
AstraZeneca PLC announced that as of August 31, 2025, its issued share capital with voting rights consists of 1,550,692,963 ordinary shares, with no shares held in Treasury. This figure is relevant for shareholders to determine their notification requirements under the UK Financial Conduct Authority’s Disclosure and Transparency Rules.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £140.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
Spark’s Take on GB:AZN Stock
According to Spark, TipRanks’ AI Analyst, GB:AZN is a Outperform.
AstraZeneca’s strong financial performance and positive earnings call are the most significant factors contributing to its score. The technical analysis indicates a potential overbought condition, and the valuation suggests the stock is relatively expensive. Despite these concerns, the company’s robust pipeline and strategic initiatives support a positive outlook.
To see Spark’s full report on GB:AZN stock, click here.
More about AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company based in Cambridge, UK. It focuses on the discovery, development, and commercialization of prescription medicines in areas such as Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its innovative medicines are sold in more than 125 countries and used by millions of patients worldwide.
Average Trading Volume: 2,279,492
Technical Sentiment Signal: Strong Buy
Current Market Cap: £182.8B
Learn more about AZN stock on TipRanks’ Stock Analysis page.